<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0036-3634</journal-id>
<journal-title><![CDATA[Salud Pública de México]]></journal-title>
<abbrev-journal-title><![CDATA[Salud pública Méx]]></abbrev-journal-title>
<issn>0036-3634</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Salud Pública]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0036-36342016000200211</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[HPV vaccination impact on a cervical cancer screening program: methods of the FASTER-Tlalpan Study in Mexico]]></article-title>
<article-title xml:lang="es"><![CDATA[Impacto de la vacunación de VPH en un programa de tamizaje de cáncer cervical: métodos del Estudio FASTER-Tlalpan en México]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Salmerón]]></surname>
<given-names><![CDATA[Jorge]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Torres-Ibarra]]></surname>
<given-names><![CDATA[Leticia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bosch]]></surname>
<given-names><![CDATA[F Xavier]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cuzick]]></surname>
<given-names><![CDATA[Jack]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lörincz]]></surname>
<given-names><![CDATA[Attila]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Wheeler]]></surname>
<given-names><![CDATA[Cosette M]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castle]]></surname>
<given-names><![CDATA[Philip E]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Robles]]></surname>
<given-names><![CDATA[Claudia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lazcano-Ponce]]></surname>
<given-names><![CDATA[Eduardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Unidad de Investigación Epidemiológica y en Servicios de Salud ]]></institution>
<addr-line><![CDATA[Cuernavaca ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Nacional de Salud Pública Centro de Investigación en Salud Poblacional ]]></institution>
<addr-line><![CDATA[Cuernavaca ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Nacional de Cancerología Unidad de Investigación en Epidemiología del Cáncer ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Institut Catala d' Oncologia Cancer Epidemiology Research Programme ]]></institution>
<addr-line><![CDATA[Barcelona ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Queen Mary University of London Centre for Cancer Prevention ]]></institution>
<addr-line><![CDATA[London ]]></addr-line>
<country>United Kingdom</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,University of New Mexico Health Sciences Center Department of Pathology]]></institution>
<addr-line><![CDATA[Albuquerque ]]></addr-line>
<country>USA</country>
</aff>
<aff id="Af7">
<institution><![CDATA[,Albert Einstein College of Medicine Department of Epidemiology and Population Health ]]></institution>
<addr-line><![CDATA[Bronx ]]></addr-line>
<country>USA</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2016</year>
</pub-date>
<volume>58</volume>
<numero>2</numero>
<fpage>211</fpage>
<lpage>219</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0036-36342016000200211&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0036-36342016000200211&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0036-36342016000200211&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: To outline the design of a clinical trial to evaluate the impact of HPV vaccination as part of a hrHPV-based primary screening program to extend screening intervals.  Materials and methods: A total of 18,000 women aged 25-45 years, attending the regular cervical cancer-screening program in primary health care services in Tlalpan, Mexico City, will be invited to the study. Eligible participants will be assigned to one of three comparison groups: 1) HPV16/18 vaccine and hrHPV-based screening; 2) HPV6/11/16/18 vaccine and hrHPV-based screening; 3) Control group who will receive only hrHPV-based screening. Strict surveillance of hrHPV persistent infection and occurrence of precancerous lesions will be conducted to estimate safety profiles at different screening intervals; participants will undergo diagnosis confirmation and treatment as necessary.  Conclusion: The FASTER-Tlalpan Study will provide insights into new approaches of cervical cancer prevention programs. It will offer valuable information on potential benefits of combining HPV vaccination and hrHPV-based screening to safety extend screening intervals.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Describir los métodos de un ensayo clínico que permita evaluar el impacto de la incorporación de la vacunación contra VPH en el programa de detección oportuna de cáncer cervical con el fin de ampliar los intervalos de tamizaje.  Material y métodos: Un total de 18 000 mujeres entre 25 y 45 años, usuarias del programa de detección oportuna de cáncer cervical de la Ciudad de México en Tlalpan, serán invitadas a participar en el estudio. Las mujeres elegibles serán aleatorizadas a uno de tres grupos de comparación: 1) Vacunación contra VPH16/18 y tamizaje con VPHar; 2) Vacunación contra VPH6/11/16/18 y tamizadas con VPHar; 3) Grupo control que será sólo tamizado con VPHar. Se llevará a cabo una estrecha vigilancia de la infección persistente de VPHar y de la ocurrencia de lesiones precancerosas, con el fin de estimar el perfil de seguridad de intervalos de tamizaje de distinta duración. Todas las participantes contarán con procedimientos de confirmación diagnóstica y tratamiento en caso necesario.  Conclusión: El estudio FASTER-Tlalpan introducirá una nueva visión de la implementación de nuevos abordajes en la prevención de cáncer cervical. Ofrecerá información de los potenciales beneficios de la combinación de la vacunación contra VPH y el tamizaje basado en VPHar para extender los intervalos de tamizaje.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[cervical intraepithelial neoplasia]]></kwd>
<kwd lng="en"><![CDATA[HPV]]></kwd>
<kwd lng="en"><![CDATA[mass screening]]></kwd>
<kwd lng="en"><![CDATA[vaccination]]></kwd>
<kwd lng="en"><![CDATA[Mexico]]></kwd>
<kwd lng="es"><![CDATA[neoplasia intraepitelial cervical]]></kwd>
<kwd lng="es"><![CDATA[VPH]]></kwd>
<kwd lng="es"><![CDATA[tamizaje masivo]]></kwd>
<kwd lng="es"><![CDATA[vacunación, México]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="book">
<collab>GLOBOCAN 2012 v1.0</collab>
<source><![CDATA[Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11]]></source>
<year>2013</year>
<publisher-name><![CDATA[International Agency for Research on Cancer]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bruni]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Barrionuevo-Rosas]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Albero]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Aldea]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Serrano]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Valencia]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in the World]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Human papillomavirus is a necessary cause of invasive cervical cancer worldwide]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walboomers]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Manos]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Bosch]]></surname>
<given-names><![CDATA[FX]]></given-names>
</name>
<name>
<surname><![CDATA[Kummer]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[KV]]></given-names>
</name>
</person-group>
<source><![CDATA[J Pathol]]></source>
<year>1999</year>
<volume>189</volume>
<page-range>12-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Human papillomavirus genotype attribution in invasive cervical cancer a retrospective cross-sectional worldwide study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[de Sanjose]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Quint]]></surname>
<given-names><![CDATA[WGV]]></given-names>
</name>
<name>
<surname><![CDATA[Alemany]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Geraets]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
<name>
<surname><![CDATA[Klaustermeier]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Lloveras]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet Oncol]]></source>
<year>2010</year>
<volume>11</volume>
<page-range>1048-56</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Human papillomavirus infection and the multistage carcinogenesis of cervical cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schiffman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wentzensen]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer Epidemiol Biomarkers Prev]]></source>
<year>2013</year>
<volume>22</volume>
<page-range>553-60</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="">
<collab>Cervical Cancer Action</collab>
<source><![CDATA[Progress in cervical cancer prevention.The CCA report card 2015]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Meeting of the immunization Strategic Advisory Group of Experts, November 2006--conclusions and recommendations]]></article-title>
<collab>World Health Organization</collab>
<source><![CDATA[Wkly Epidemiol Rec]]></source>
<year>2007</year>
<volume>82</volume>
<page-range>1-16</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goldie]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kohli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Grima]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Weinstein]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Wright]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
<name>
<surname><![CDATA[Bosch]]></surname>
<given-names><![CDATA[FX]]></given-names>
</name>
</person-group>
<source><![CDATA[JNCI]]></source>
<year>2004</year>
<volume>96</volume>
<page-range>604-15</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Block]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Nolan]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sattler]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Barr]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Giacoletti]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
<name>
<surname><![CDATA[Marchant]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
</person-group>
<source><![CDATA[Pediatrics]]></source>
<year>2006</year>
<volume>118</volume>
<page-range>2135-45</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muñoz]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Mendez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Posso]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Molano]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[van den Brule]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ronderos]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[J Infect Dis]]></source>
<year>2004</year>
<volume>190</volume>
<page-range>2077-87</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Skinner]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Szarewski]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Romanowski]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Garland]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Lazcano-Ponce]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Salmerón]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet]]></source>
<year>2014</year>
<volume>384</volume>
<page-range>2213-27</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil in adult women]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Luna]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Plata]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Correa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Maldonado]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Nossa]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[PLoS one]]></source>
<year>2013</year>
<volume>8</volume>
<page-range>e83431</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cross-protective efficacy of two human papillomavirus vaccines a systematic review and meta-analysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malagon]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Drolet]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Boily]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Franco]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Jit]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Brisson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet Infect Dis]]></source>
<year>2012</year>
<volume>12</volume>
<page-range>781-9</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia a repeat cross-sectional study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tabrizi]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
<name>
<surname><![CDATA[Brotherton]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Kaldor]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Skinner]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Bateson]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet Infect Dis]]></source>
<year>2014</year>
<volume>14</volume>
<page-range>958-66</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[HPV-FASTER: broadening the scope for prevention of HPV-related cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bosch]]></surname>
<given-names><![CDATA[FX]]></given-names>
</name>
<name>
<surname><![CDATA[Robles]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Diaz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Arbyn]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Baussano]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Clavel]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Nat Rev Clin Oncol]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Serrano]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Alemany]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Tous]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bruni]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Clifford]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Weiss]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<source><![CDATA[Infect Agent Cancer]]></source>
<year>2012</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>38</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule Observational cohort of young women in Australia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brotherton]]></surname>
<given-names><![CDATA[JML]]></given-names>
</name>
<name>
<surname><![CDATA[Malloy]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Budd]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Saville]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Drennan]]></surname>
<given-names><![CDATA[KT]]></given-names>
</name>
<name>
<surname><![CDATA[Gertig]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<source><![CDATA[Papillomavirus Research]]></source>
<year>2015</year>
<volume>1</volume>
<page-range>59-73</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine combined analysis of data from the Costa Rica Vaccine and PATRICIA trials]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kreimer]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Struyf]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Del Rosario-Raymundo]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Hildesheim]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Skinner]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Wacholder]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet Oncol]]></source>
<year>2015</year>
<volume>16</volume>
<page-range>775-86</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="book">
<collab>Instituto Nacional de Estadística, Geografía e Informática</collab>
<source><![CDATA[Censo de Población y vivienda 2010]]></source>
<year>2012</year>
<publisher-loc><![CDATA[México, D.F ]]></publisher-loc>
<publisher-name><![CDATA[INEGI]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cervical HPV infection and neoplasia in a large population-based prospective study the Manchester cohort]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peto]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gilham]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Deacon]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Binns]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<source><![CDATA[Br J Cancer]]></source>
<year>2004</year>
<volume>91</volume>
<page-range>942-53</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women a systematic review &amp; meta-analysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Castellsague]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Giuliano]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<source><![CDATA[BMC Infect Dis]]></source>
<year>2011</year>
<volume>11</volume>
<page-range>13</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prophylactic vaccination against human papillomavirus infection and disease in women a systematic review of randomized controlled trials]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rambout]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hopkins]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hutton]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Fergusson]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[CMAJ]]></source>
<year>2007</year>
<volume>177</volume>
<page-range>469-79</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="">
<collab>Comisión Federal para la Protección contra Riesgos Sanitarios</collab>
<source><![CDATA[Consulta de Registros Sanitarios 2015]]></source>
<year></year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
